Literature DB >> 27289334

Cancer and inflammatory bowel disease in the elderly.

Sasha Taleban1, Emad Elquza2, Corinne Gower-Rousseau3, Laurent Peyrin-Biroulet4.   

Abstract

Cancer may be a complication of inflammatory bowel disease (IBD) or its treatments. In older Crohn's disease and ulcerative colitis patients, the risk of malignancy is of particular concern. IBD diagnosis at an advanced age is associated with earlier development of colitis-associated colorectal cancer. Thiopurine use in older IBD patients is tied to an increased risk of non-Hodgkin's lymphoma, nonmelanoma skin cancer, and urinary tract cancers. Additionally, older age is accompanied by multimorbidity, an increased risk of malnutrition, and decreased life expectancy, factors that complicate the management of cancer in the elderly. The optimal approach to the increased risk of malignancy in older age IBD is appropriate cancer screening and medical treatment. This may include age-specific colorectal cancer screening and limiting UV radiation exposure. With a growing number of older IBD patients, further studies are necessary to delineate the risk of cancer in this population.
Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crohn's disease; Malignancy; Older; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27289334     DOI: 10.1016/j.dld.2016.05.006

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  12 in total

Review 1.  Crohn's Disease and the Risk of Cancer.

Authors:  Evie Carchman
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

2.  Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study.

Authors:  Preeti Shashi; Dharmesh Gopalakrishnan; Malav P Parikh; Bo Shen; Gursimran Kochhar
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-09-17

Review 3.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

4.  Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.

Authors:  Alyce S Adams; Jeanne M Madden; Fang Zhang; Christine Y Lu; Dennis Ross-Degnan; Angelina Lee; Stephen B Soumerai; Dan Gilden; Neetu Chawla; Jennifer J Griggs
Journal:  Value Health       Date:  2017-07-06       Impact factor: 5.725

5.  Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.

Authors:  Nabeel Khan; Carlos Vallarino; Trevor Lissoos; Umar Darr; Michelle Luo
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

6.  Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone.

Authors:  Sally A Coulthard; Phil Berry; Sarah McGarrity; Simon McLaughlin; Azhar Ansari; Christopher P F Redfern
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

7.  Reduction of Inflammation and Colon Injury by a Spearmint Phenolic Extract in Experimental Bowel Disease in Mice.

Authors:  Rosa Direito; João Rocha; Ana Lima; Maria Margarida Gonçalves; Maria Paula Duarte; Vanessa Mateus; Catarina Sousa; Adelaide Fernandes; Rui Pinto; Ricardo Boavida Ferreira; Bruno Sepodes; Maria-Eduardo Figueira
Journal:  Medicines (Basel)       Date:  2019-06-06

Review 8.  Inflammatory bowel disease and prostate cancer risk: A systematic review.

Authors:  Anoud Haddad; Mohammed Qussay Al-Sabbagh; Hashim Al-Ani; Abdel Muez Siyam; Emad Aborajooh; Takehiro Iwata; Shoji Kimura; Shahrokh F Shariat; Mohammad Abufaraj
Journal:  Arab J Urol       Date:  2020-05-19

Review 9.  Phenolic Compounds Impact on Rheumatoid Arthritis, Inflammatory Bowel Disease and Microbiota Modulation.

Authors:  Rosa Direito; João Rocha; Bruno Sepodes; Maria Eduardo-Figueira
Journal:  Pharmaceutics       Date:  2021-01-22       Impact factor: 6.321

10.  Immunosuppression and Malignant Neoplasms: Risk-Benefit Assessment in Patients with Inflammatory Bowel Disease.

Authors:  Bruna Damásio Moutinho; Jaqueline Ribeiro de Barros; Julio Pinheiro Baima; Rogerio Saad-Hossne; Ligia Yukie Sassaki
Journal:  Am J Case Rep       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.